Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, Feilotter H, Hansen AR, Hyrcza M, Krzyzanowska M, Melosky B, Noujaim J, Purgina B, Ruether D, Simmons CE, Soulieres D, Torlakovic EE, Tsao MS. Bebb DG, et al. Among authors: banerji s. Curr Oncol. 2021 Jan 15;28(1):523-548. doi: 10.3390/curroncol28010053. Curr Oncol. 2021. PMID: 33467570 Free PMC article.
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V. Melosky B, et al. Among authors: banerji s. Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9. Curr Oncol. 2016. PMID: 27330348 Free PMC article.
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS. Laurie SA, et al. Among authors: banerji s. Curr Oncol. 2019 Feb;26(1):e81-e93. doi: 10.3747/co.26.4116. Epub 2019 Feb 1. Curr Oncol. 2019. PMID: 30853813 Free PMC article.
A Canadian guideline on the use of next-generation sequencing in oncology.
Yip S, Christofides A, Banerji S, Downes MR, Izevbaye I, Lo B, MacMillan A, McCuaig J, Stockley T, Yousef GM, Spatz A. Yip S, et al. Among authors: banerji s. Curr Oncol. 2019 Apr;26(2):e241-e254. doi: 10.3747/co.26.4731. Epub 2019 Apr 1. Curr Oncol. 2019. PMID: 31043833 Free PMC article.
Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.
Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leighl NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS. Bebb DG, et al. Among authors: banerji s. Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1. Curr Oncol. 2019. PMID: 31548824 Free PMC article.
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Meyers DE, Banerji S. Meyers DE, et al. Among authors: banerji s. Curr Oncol. 2020 Apr;27(Suppl 2):S106-S114. doi: 10.3747/co.27.5549. Epub 2020 Apr 1. Curr Oncol. 2020. PMID: 32368180 Free PMC article. Review.
Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma.
Simmons C, Deyell RJ, MacNeill AJ, Vera-Badillo FE, Smrke A, Abdul Razak AR, Banerji S, McLeod D, Noujaim J. Simmons C, et al. Among authors: banerji s. Int J Cancer. 2021 Nov 1;149(9):1691-1704. doi: 10.1002/ijc.33723. Epub 2021 Aug 4. Int J Cancer. 2021. PMID: 34213775 Free article.
257 results